Adaptive Biotechnologies Corp vs Jabil Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Jabil Inc trades at $361.7 (market cap $37.37B). The key difference: Jabil Inc is far larger — about 9.3× Adaptive Biotechnologies Corp's market cap, and Jabil Inc pays a 0.09% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | JBL | |
|---|---|---|
Market Cap | $4.04B | $37.37B |
Sector | Health | Technology |
52-Week High | $25.45 | $385.50 |
52-Week Low | $12.30 | $192.49 |
Enterprise Value | $4.10B | $39.90B |
Dividend Yield | — | 0.09% |
Trailing returns across standard periods
Latest headlines on both assets
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →